Boston Scientific (BSX)
(Delayed Data from NYSE)
$81.60 USD
+0.23 (0.28%)
Updated Sep 6, 2024 04:00 PM ET
After-Market: $81.64 +0.04 (0.05%) 7:58 PM ET
2-Buy of 5 2
C Value B Growth F Momentum C VGM
Price, Consensus and EPS Surprise
BSX 81.60 +0.23(0.28%)
Will BSX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for BSX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BSX
Align Technology Stock Dips on Macroeconomic Issues, FX Headwind
COO Stock Up 0.4% Following the Launch of New Inserter for Paragard IUD
BSX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Are Medical Stocks Lagging Addex Therapeutics (ADXN) This Year?
Abbott's Lingo CGM System Gains U.S. Availability: Stock to Gain?
Reasons to Retain Revvity Stock in Your Portfolio for Now
Other News for BSX
Election 2024: Where To Put Your Money Ahead of the Vote
Catalyst Watch: Apple's iPhone event, Oracle earnings, Google antitrust trial, and the August CPI print
50 stocks to invest during the bull steepening – Part 1
Russell companies with the lowest tax rates expected to generate $1B in 2025 – GS
Buy Rating for Boston Scientific: Positive Trends and Growth Potential Ahead